CD4 and lung carcinoma: Opposingly, activin treatment reduced the tumor burden, increased the survival time, and increased the pro-inflammatory profile of isolated CD4+ T-cells in a Lewis lung carcinoma (LLC) mouse model of lung cancer [15].